Is 2-deoxy-2-[(18)F]fluoro-D-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients?(95 visite) Salvatore B, Caprio MG, Fonti R, D'Amico D, Fraioli F, Salvatore M, Pace L
Impact factor: 2.256, Impact factor a 5 anni: 2.015
Url: Non disponibile.
Parole chiave: Pet Ct, Brain, Head, Whole-Body Acquisition,
*** IBB - CNR *** Consiglio Nazionale delle Ricerche-Istituto di Biostrutture e Bioimmagini, Napoli, Italy. Dipartimento ad attivita integrate di Diagnostica Morfologica e Funzionale, Radioterapia, Medicina Legale. Universita degli Studi di Napoli Federico II, Italy. Fondazione SDN-IRCCS, Napoli, Italy. Dipartimento di Medicina e Chirurgia, Universita degli Studi di Salerno, Italy. Dipartimento di Medicina e Chirurgia, Università degli Studi di Salerno, Italy
AIM: To assess whether performing routinely 2-deoxy-2- [(18) F] fluoro-D-glucose PET/CT ((18) FDG PET/CT) scan from the upper thigh to the vertex of skull is clinically relevant. MATERIALS AND METHODS: 3502 (1634 female; mean-age 60+16) consecutive patients undergoing (18) FDG PET/CT were retrospectively analyzed. Patients were divided in 10 groups according to primary malignancy. Chi-square analysis was used to assess differences among proportions. A p value < 0. 05 was considered significant. RESULTS: (18) FDG PET/CT was positive in head district in 130/3502 (3, 7%) patients. In all patients lesions were unknown before PET/CT examination. PET/CT showed 158 positive brain/head uptake in the 130 patients. The 158 lesions were localized in: brain (43/158; 27%), bone (52/158; 33%), lymph node (1/158; 0, 6%), soft tissue (55/158; 35%) and other sites (7/158; 4, 4%). According to each group, patients were positive in the head district in 1. 0% for Gastrointestinal Cancer (7/690), 3. 0 % for Genitourinary Cancer (3/101), 3. 7 % for Haemathologic Cancer (59/1590), 2. 7 % for Gynaecologic Cancer (3/112), 7. 8% for Head-Neck-Thyroid and Parathyroid Cancer (26/331), 3. 5% for Breast Cancer (7/200), 2. 6% for Lung Cancer (7/271), 3. 4% for Melanoma (2/59), 7. 4% for Sarcoma (2/27), 11. 6% for Unknown Primary Tumour (14/121). CONCLUSION: Our data show a relatively high incidence of brain/head lesion in patients with Unknown Primary Tumour